ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1646723
This article is part of the Research TopicDevelopment and Future of Personalized and Precision Medicine Approaches for Urologic CancersView all 3 articles
Prognostic Risk Factors and the Role of Systemic Inflammatory Response Index in Predicting Outcomes for Non-Muscle-Invasive Bladder Cancer
Provisionally accepted
- 1Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, China
- 2College of Biological and Food Engineering, Huanghuai University, Zhumadian, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Non-muscle-invasive bladder cancer (NMIBC) presents a variable prognosis, with a significant risk of recurrence and progression. Traditional clinicopathological factors provide limited prognostic accuracy, necessitating additional biomarkers. This study aimed to evaluate the prognostic role of the systemic inflammatory response index (SIRI) and traditional risk factors in predicting outcomes in NMIBC patients. Methods: We retrospectively analyzed 158 NMIBC patients who underwent transurethral resection of bladder tumor (TURBT) between January 2021 and October 2023. Patients were stratified into recurrence/non-recurrence and progression/non-progression groups. Clinical and pathological characteristics were compared using Chi-square tests, t-tests, or Fisher’s exact tests as appropriate. Receiver operating characteristic (ROC) analysis identified the optimal SIRI cutoff, which was used for Kaplan-Meier survival analysis and Cox regression to assess independent prognostic factors for progression-free survival (PFS). Results: The optimal SIRI cutoff value for predicting progression was 0.716 (area under the curve [AUC] = 0.689, sensitivity = 0.689, specificity = 0.718). Patients with SIRI ≥ 0.716 exhibited significantly higher progression risk (P = 0.012) and poorer PFS (Log-rank P < 0.05). Multivariate Cox regression confirmed tumor count (HR = 3.273, 95% CI: 1.003–10.691, P = 0.049), primary diagnosis status (HR = 2.563, 95% CI: 1.012–7.214, P = 0.045), and high SIRI (HR = 2.979, 95% CI: 1.110–8.027, P = 0.031) as independent predictors of PFS. Recurrence analysis further revealed that high SIRI was associated with markedly increased recurrence rates in both Ta (50.0% vs. 6.2%, P < 0.001) and T1 subgroups (73.9% vs. 32.3%, P < 0.001). Conclusions: SIRI is a significant predictor of disease progression in NMIBC, although it is not associated with RFS. When combined with clinicopathological factors such as tumor stage, grade, count, and primary diagnosis status, SIRI can enhance risk stratification in NMIBC, aiding personalized management.
Keywords: Non-muscle-invasive bladder cancer, systemic inflammatory response index, Recurrence-free survival, Progression-free survival, prognostic factors
Received: 13 Jun 2025; Accepted: 29 Aug 2025.
Copyright: © 2025 Gui, Guo, Liu, Jiao and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiu-Hua Wen, Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.